KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medtronic (MDT) Accumulated Expenses (2016 - 2026)

Medtronic's Accumulated Expenses history spans 12 years, with the latest figure at $2.6 billion for Q1 2026.

  • For Q1 2026, Accumulated Expenses rose 13.15% year-over-year to $2.6 billion; the TTM value through Jan 2026 reached $2.6 billion, up 13.15%, while the annual FY2025 figure was $2.5 billion, 5.85% up from the prior year.
  • Accumulated Expenses for Q1 2026 was $2.6 billion at Medtronic, up from $2.1 billion in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $2.6 billion in Q1 2026 and bottomed at $1.7 billion in Q3 2023.
  • The 5-year median for Accumulated Expenses is $2.0 billion (2025), against an average of $2.1 billion.
  • The largest annual shift saw Accumulated Expenses decreased 14.54% in 2022 before it rose 21.86% in 2024.
  • A 5-year view of Accumulated Expenses shows it stood at $1.7 billion in 2022, then rose by 2.15% to $1.8 billion in 2023, then increased by 7.68% to $1.9 billion in 2024, then grew by 12.52% to $2.1 billion in 2025, then rose by 21.17% to $2.6 billion in 2026.
  • Per Business Quant, the three most recent readings for MDT's Accumulated Expenses are $2.6 billion (Q1 2026), $2.1 billion (Q4 2025), and $2.0 billion (Q3 2025).